STOCK TITAN

NUO THERAPEUTICS INC NEW - AURX STOCK NEWS

Welcome to our dedicated page for NUO THERAPEUTICS NEW news (Ticker: AURX), a resource for investors and traders seeking the latest updates and insights on NUO THERAPEUTICS NEW stock.

NUO Therapeutics Inc NEW (AURX) is a biotherapeutics company specializing in the development and commercialization of innovative therapies for various medical conditions. With a focus on regenerative medicine and advanced wound care solutions, NUO Therapeutics is committed to improving patient outcomes and quality of life. The company's cutting-edge products and research initiatives have garnered recognition in the healthcare industry, positioning it as a leader in the field of biotechnology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Nuo Therapeutics, Inc. (OTCQB: AURX) has announced a strategic equity agreement with Pacific Medical, Inc., which includes an initial $500,000 purchase of common stock. This partnership aims to enhance the distribution and sales of the Aurix product, a biodynamic therapy for chronic wounds. With approximately $4.5 million raised this year, Nuo is positioned to further its commercial goals. The North American advanced wound care market is projected to reach $3.6 billion in 2022, driven by an increasing prevalence of chronic wounds. Nuo is also exploring potential uplisting to a national exchange.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
59.26%
Tags
none
Rhea-AI Summary

Nuo Therapeutics announced awareness of an unsolicited mini-tender offer from Alternative Liquidity Index, LP to purchase 1,820,000 shares, roughly 4.9% of its outstanding shares, at $0.01 each. The company emphasizes it is not associated with this offer and warns investors about the risks of mini-tender offers, which lack comprehensive SEC disclosure protections. The offered price is significantly lower than the recent warrant exercise price of $0.20 per share. Nuo intends to file overdue financial reports to regain compliance with SEC obligations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Nuo Therapeutics, Inc. (OTC Pink: AURX) announced on April 20, 2021, the publication of a final decision memo from the Centers for Medicare & Medicaid Services (CMS) regarding coverage for autologous platelet-rich plasma (PRP) therapy for chronic non-healing diabetic foot ulcers (DFUs). Medicare will cover PRP treatments for up to 20 weeks, with specific FDA clearance requirements for devices. CEO David Jorden highlighted the significance of this decision and the company's efforts to improve clinical data since its previous non-coverage ruling in 2008. The company aims to ensure Aurix is accessible to patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.71%
Tags
none
-
Rhea-AI Summary

Nuo Therapeutics, Inc. (OTC Pink: AURX) announced the closing of a recapitalization and exchange agreement that simplifies its capital structure. The agreement involved an exchange of Series A Preferred Stock for 2.7 million common shares and conversion of approximately $330,000 of secured notes into 838,487 shares. The transaction leaves the company with no debt and around 29.2 million shares outstanding. The CEO noted potential improvements pending a decision from CMS regarding national coverage for the Aurix product, crucial for the company's future viability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.41%
Tags
none

FAQ

What is the market cap of NUO THERAPEUTICS NEW (AURX)?

The market cap of NUO THERAPEUTICS NEW (AURX) is approximately 40.2M.

What is NUO Therapeutics Inc NEW (AURX) focused on?

NUO Therapeutics is focused on developing and commercializing innovative therapies in the fields of regenerative medicine and advanced wound care.

What sets NUO Therapeutics apart in the healthcare industry?

NUO Therapeutics stands out for its cutting-edge products and research initiatives that aim to improve patient outcomes and quality of life.

What is NUO Therapeutics' core business model?

NUO Therapeutics' core business revolves around biotherapeutics, with a strong emphasis on regenerative medicine and advanced wound care solutions.

How does NUO Therapeutics contribute to the biotechnology sector?

NUO Therapeutics contributes to the biotechnology sector through its innovative therapies and research efforts that address various medical conditions.

What is NUO Therapeutics Inc NEW's mission?

NUO Therapeutics is dedicated to enhancing patient care by developing and commercializing groundbreaking therapies in regenerative medicine and advanced wound care.

Are there any recent achievements or milestones NUO Therapeutics has reached?

NUO Therapeutics has achieved recognition in the healthcare industry for its advancements in biotechnology and its commitment to improving patient outcomes.

How does NUO Therapeutics collaborate with industry partners?

NUO Therapeutics collaborates with industry partners to further research, development, and commercialization efforts in the field of regenerative medicine and advanced wound care.

What can investors expect from NUO Therapeutics Inc NEW (AURX)?

Investors can anticipate continued growth and innovation from NUO Therapeutics as it remains at the forefront of biotechnology and healthcare advancements.

Where can I find more information about NUO Therapeutics Inc NEW (AURX)?

For more information about NUO Therapeutics, visit the company's official website or contact David Jorden at djorden@nuot.com.

How does NUO Therapeutics contribute to improving patient outcomes?

NUO Therapeutics contributes to improving patient outcomes through its development of advanced therapies in regenerative medicine and wound care.

NUO THERAPEUTICS INC NEW

OTC:AURX

AURX Rankings

AURX Stock Data

40.20M
19.47M
63.45%
5.17%
Biotechnology
Healthcare
Link
United States of America
Houston